Acute Myeloid Leukemia Archives - Cancer Therapy Advisor

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

Whole-Genome Sequencing Shows Promise for Risk Stratification in AML, MDS

By

April 26, 2021

Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinici

Pediatric Cancer

Risk Factors for Pediatric Hemorrhagic Cystitis Following HCT

By

Leah Lawrence

April 14, 2021

Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.

Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations that co

Hematologic Cancers

Genome Sequencing: An Alternative for Risk Stratification in Myeloid Cancers

By

Leah Lawrence

April 13, 2021

A team of investigators assessed the application of whole-genome sequencing for genomic profiling of patients with acute myeloid leukemia or myelodysplastic syndromes.

Hematologic Cancers

Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia

By

Vicki Moore, PhD

April 8, 2021

Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.

Hematologic Cancers

Cytogenetics Predict Outcomes to Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

By

Patricia Chaney

April 7, 2021

Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

Hematologic Cancers

Thymoglobulin as GVHD Prophylaxis in AML Conditioning Regimens

By

Patricia Chaney

March 8, 2021

Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.

Venetoclax and ibrutinib are therapeutic agents for CLL.

Hematologic Cancers

Fractionated Gemtuzumab Ozogamicin Not Linked With Increased VOD/SOS Risk in Acute Myeloid Leukemia

By

Jonathan Goodman, MPhil

March 8, 2021

Among patients with de novo AML, fractionated-dose gemtuzumab ozogamicin does not appear to increase the risk of hepatic VOD/SOS after HSCT.

Hematologic Cancers

Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML

By

Rachel Narozniak, MA

February 19, 2021

Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).

Hematologic Cancers

American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults

By

Julie Scott, ANP-BC, AOCNP

February 10, 2021

This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.

Hematologic Cancers

Uncertainties Surround Optimal Dosing of Cytarabine in AML

By

Susan Moench, PhD, PA-C

January 14, 2021

This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).